Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Improvements in insulin resistance after anti-TNF-α therapy have been reported in inflammatory conditions, although no changes were noted in adult patients with Crohn's disease. There is no information concerning insulin resistance and substrate metabolism in children with Crohn's disease after anti-TNF-α therapy. Our aim was to describe changes in carbohydrate and lipid metabolism in children with active Crohn's disease after their initial dose of infliximab. Children with active Crohn's disease underwent measurement of plasma insulin and glucose just before and 2 wk after their initial infusion of infliximab, an anti-TNF-α antibody. In addition, resting energy expenditure, with determination of both carbohydrate and lipid oxidation rates, was determined. Measurements were conducted in both fasting and parenterally fed states. Despite no changes in resting energy expenditure, a significant reduction (p < 0.05) in RQ (5%) and carbohydrate oxidation rate (24%), with a corresponding increase in lipid oxidation rate (42%) was found during parenteral nutrition infusion. No differences in plasma insulin, glucose, and insulin resistance were noted when comparing pre- and postinfliximab measurements.

Original languageEnglish
Pages (from-to)673-676
Number of pages4
JournalPediatric Research
Volume64
Issue number6
DOIs
StatePublished - Dec 2008

Fingerprint

Carbohydrate Metabolism
Lipid Metabolism
Crohn Disease
Insulin Resistance
Energy Metabolism
Carbohydrates
Parenteral Infusions
Insulin
Lipids
Glucose
Parenteral Nutrition
Therapeutics
Anti-Idiotypic Antibodies
Fasting
Pediatric Crohn's disease
Infliximab

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease. / Steiner, Steven; Pfefferkorn, Marian; Fitzgerald, Joseph F.; Denne, Scott.

In: Pediatric Research, Vol. 64, No. 6, 12.2008, p. 673-676.

Research output: Contribution to journalArticle

@article{aa3c626ac61b4608b40f1aacb4b286c7,
title = "Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease",
abstract = "Improvements in insulin resistance after anti-TNF-α therapy have been reported in inflammatory conditions, although no changes were noted in adult patients with Crohn's disease. There is no information concerning insulin resistance and substrate metabolism in children with Crohn's disease after anti-TNF-α therapy. Our aim was to describe changes in carbohydrate and lipid metabolism in children with active Crohn's disease after their initial dose of infliximab. Children with active Crohn's disease underwent measurement of plasma insulin and glucose just before and 2 wk after their initial infusion of infliximab, an anti-TNF-α antibody. In addition, resting energy expenditure, with determination of both carbohydrate and lipid oxidation rates, was determined. Measurements were conducted in both fasting and parenterally fed states. Despite no changes in resting energy expenditure, a significant reduction (p < 0.05) in RQ (5{\%}) and carbohydrate oxidation rate (24{\%}), with a corresponding increase in lipid oxidation rate (42{\%}) was found during parenteral nutrition infusion. No differences in plasma insulin, glucose, and insulin resistance were noted when comparing pre- and postinfliximab measurements.",
author = "Steven Steiner and Marian Pfefferkorn and Fitzgerald, {Joseph F.} and Scott Denne",
year = "2008",
month = "12",
doi = "10.1203/PDR.0b013e318186dde2",
language = "English",
volume = "64",
pages = "673--676",
journal = "Pediatric Research",
issn = "0031-3998",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Carbohydrate and lipid metabolism following infliximab therapy in pediatric Crohn's disease

AU - Steiner, Steven

AU - Pfefferkorn, Marian

AU - Fitzgerald, Joseph F.

AU - Denne, Scott

PY - 2008/12

Y1 - 2008/12

N2 - Improvements in insulin resistance after anti-TNF-α therapy have been reported in inflammatory conditions, although no changes were noted in adult patients with Crohn's disease. There is no information concerning insulin resistance and substrate metabolism in children with Crohn's disease after anti-TNF-α therapy. Our aim was to describe changes in carbohydrate and lipid metabolism in children with active Crohn's disease after their initial dose of infliximab. Children with active Crohn's disease underwent measurement of plasma insulin and glucose just before and 2 wk after their initial infusion of infliximab, an anti-TNF-α antibody. In addition, resting energy expenditure, with determination of both carbohydrate and lipid oxidation rates, was determined. Measurements were conducted in both fasting and parenterally fed states. Despite no changes in resting energy expenditure, a significant reduction (p < 0.05) in RQ (5%) and carbohydrate oxidation rate (24%), with a corresponding increase in lipid oxidation rate (42%) was found during parenteral nutrition infusion. No differences in plasma insulin, glucose, and insulin resistance were noted when comparing pre- and postinfliximab measurements.

AB - Improvements in insulin resistance after anti-TNF-α therapy have been reported in inflammatory conditions, although no changes were noted in adult patients with Crohn's disease. There is no information concerning insulin resistance and substrate metabolism in children with Crohn's disease after anti-TNF-α therapy. Our aim was to describe changes in carbohydrate and lipid metabolism in children with active Crohn's disease after their initial dose of infliximab. Children with active Crohn's disease underwent measurement of plasma insulin and glucose just before and 2 wk after their initial infusion of infliximab, an anti-TNF-α antibody. In addition, resting energy expenditure, with determination of both carbohydrate and lipid oxidation rates, was determined. Measurements were conducted in both fasting and parenterally fed states. Despite no changes in resting energy expenditure, a significant reduction (p < 0.05) in RQ (5%) and carbohydrate oxidation rate (24%), with a corresponding increase in lipid oxidation rate (42%) was found during parenteral nutrition infusion. No differences in plasma insulin, glucose, and insulin resistance were noted when comparing pre- and postinfliximab measurements.

UR - http://www.scopus.com/inward/record.url?scp=57849149043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57849149043&partnerID=8YFLogxK

U2 - 10.1203/PDR.0b013e318186dde2

DO - 10.1203/PDR.0b013e318186dde2

M3 - Article

C2 - 18679167

AN - SCOPUS:57849149043

VL - 64

SP - 673

EP - 676

JO - Pediatric Research

JF - Pediatric Research

SN - 0031-3998

IS - 6

ER -